Markets

Will the TOFA compound enter human clinical trials for obesity treatment by December 31, 2027?

Yes0%No0%
Loading...

About this market

This market resolves to Yes if the molecular compound 5-tetradecyloxy-2-furoic acid (TOFA) begins human clinical trials focused on obesity treatment by December 31, 2027. TOFA has shown promising results in mice for increasing energy usage and reducing body fat. The resolution will be based on official announcements from scientific institutions or pharmaceutical companies.

Rules

  • Market closes at 12/31/2027.
  • Logic weighted resolution applies.